FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
Portfolio Pulse from Vandana Singh
The FDA has lifted the partial clinical hold on Arcellx Inc's iMMagine-1 Phase 2 Clinical Program. The decision comes after modifications were made to the trial protocol to better manage the risk of adverse events. Arcellx has retrained clinical sites and expanded treatment options for therapies that patients can receive. Preliminary data from the study is expected in the second half of 2024. Arcellx's shares are down 0.09% at $33.66 premarket.
August 15, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The FDA's decision to lift the hold on Arcellx's clinical program could potentially boost investor confidence in the company. However, the slight drop in premarket shares indicates a cautious market response.
The FDA's decision to lift the hold on Arcellx's clinical program is a positive development for the company. However, the market's response has been cautious, with a slight drop in premarket shares. This could be due to the fact that preliminary data from the study is not expected until the second half of 2024, which means there is still a significant amount of uncertainty surrounding the outcome of the trial.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100